Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down - What's Next?

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $28.74, but opened at $28.01. Dyne Therapeutics shares last traded at $28.30, with a volume of 74,558 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on DYN. StockNews.com lowered shares of Dyne Therapeutics from a "hold" rating to a "sell" rating in a report on Monday, September 16th. Morgan Stanley lifted their target price on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 14th. Oppenheimer reissued an "outperform" rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. HC Wainwright restated a "buy" rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, September 4th. Finally, JPMorgan Chase & Co. cut Dyne Therapeutics from an "overweight" rating to a "neutral" rating and reduced their target price for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $50.60.

Dyne Therapeutics Stock Performance

The company's fifty day moving average price is $34.65 and its 200 day moving average price is $34.90. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of -8.02 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.02. As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO John Cox bought 32,000 shares of the firm's stock in a transaction on Wednesday, September 4th. The stock was purchased at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the transaction, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. This trade represents a -100.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In other Dyne Therapeutics news, CEO John Cox bought 32,000 shares of the business's stock in a transaction on Wednesday, September 4th. The shares were purchased at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the purchase, the chief executive officer now directly owns 8,000 shares of the company's stock, valued at approximately $264,320. The trade was a -100.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Susanna Gatti High sold 8,976 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total value of $308,864.16. Following the completion of the transaction, the chief operating officer now directly owns 131,636 shares of the company's stock, valued at approximately $4,529,594.76. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 158,975 shares of company stock valued at $5,693,789 over the last three months. Company insiders own 20.77% of the company's stock.

Hedge Funds Weigh In On Dyne Therapeutics

Several large investors have recently bought and sold shares of DYN. State of New Jersey Common Pension Fund D bought a new position in Dyne Therapeutics during the 3rd quarter valued at $1,588,000. Privium Fund Management B.V. boosted its stake in Dyne Therapeutics by 7.1% during the third quarter. Privium Fund Management B.V. now owns 15,016 shares of the company's stock valued at $539,000 after buying an additional 1,000 shares in the last quarter. Hanseatic Management Services Inc. acquired a new position in Dyne Therapeutics during the third quarter worth about $258,000. Arcadia Investment Management Corp MI raised its position in Dyne Therapeutics by 9.8% in the third quarter. Arcadia Investment Management Corp MI now owns 38,614 shares of the company's stock worth $1,387,000 after acquiring an additional 3,439 shares in the last quarter. Finally, US Bancorp DE lifted its holdings in Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company's stock valued at $49,000 after acquiring an additional 1,212 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.